2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 495

Characteristics of Metabolic Syndrome in Men and Women with Early Rheumatoid Arthritis
Abstract Number: 597

Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Abstract Number: 1812

Characterization and Prevalence of Morbus Behçet in Switzerland
Abstract Number: 1110

Characterization of CD20+ T Cells in Patients with Systemic Sclerosis
Abstract Number: 359

Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Induced Arthritis
Abstract Number: 2791

Characterization of Monoclonal Anti-PAD4 Autoantibodies from Rheumatoid Arthritis Patients: Functional Implications for Citrullination and Disease Progression
Abstract Number: 2317

Characterization of Paget´s Disease of Bone Patients from the South of Portugal (Algarve and Alentejo) – Clinical and Genetic Aspects
Abstract Number: 907

Characterization of Preferential Recognition of a Chimeric Recombinant Proteinase 3 Variant By Anti-Neutrophil Cytoplasmic Antibodies
Abstract Number: 1117

Characterization of the Esophageal Microbiome in Patients with Systemic Sclerosis (SSc)
Abstract Number: 1922

Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
Abstract Number: 1068

Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1215

Characterizing Changes in the Median Nerve during Hand Grip Using Dynamic Sonographic Imaging
Abstract Number: 2465

Characterizing Palindromic Symptoms in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study
Abstract Number: 1763

Characterizing the Gut and Plasma Metabolomes in Patients with ANCA-Associated Vasculitis
Abstract Number: 1121

Characterizing the T Cell Receptor Repertoire in Patients with Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].